Investigational Drug Information for TD-9855
✉ Email this page to a colleague
What is the drug development status for TD-9855?
TD-9855 is an investigational drug.
There have been 9 clinical trials for TD-9855.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 24th 2019.
The most common disease conditions in clinical trials are Hypotension, Pure Autonomic Failure, and Hypotension, Orthostatic. The leading clinical trial sponsors are Theravance Biopharma, Theravance Biopharma R & D, Inc., and [disabled in preview].
There are eighteen US patents protecting this investigational drug and one hundred and seventeen international patents.
Summary for TD-9855
| US Patents | 18 |
| International Patents | 117 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2019-01-24) |
| Vendors | 2 |
Recent Clinical Trials for TD-9855
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 | Theravance Biopharma | Phase 1 |
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Theravance Biopharma | Phase 3 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Theravance Biopharma | Phase 3 |
Clinical Trial Summary for TD-9855
Top disease conditions for TD-9855
Top clinical trial sponsors for TD-9855
US Patents for TD-9855
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TD-9855 | See Plans and Pricing | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-9855 | See Plans and Pricing | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-9855 | See Plans and Pricing | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-9855 | See Plans and Pricing | Methods for treating neurogenic orthostatic hypotension | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TD-9855
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TD-9855 | Argentina | AR074128 | 2028-11-14 | See Plans and Pricing |
| TD-9855 | Argentina | AR074350 | 2028-11-14 | See Plans and Pricing |
| TD-9855 | Argentina | AR114965 | 2028-11-14 | See Plans and Pricing |
| TD-9855 | Australia | AU2009313948 | 2028-11-14 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
